Hematopoietic stem cell transplantation market expansion is anticipated to be driven by the rising incidence of leukaemia and lymphoma over the course of the projected period. According to the Leukemia and Lymphoma Society's 2019 report, an estimated 176,200 Americans had leukaemia, lymphoma, or myeloma at the time of their diagnosis, and 1,399,180 of those people were still battling the disease. The need for hematopoietic stem cell transplantation is anticipated to rise in response to the rising incidence rate, fueling the market for hematopoietic stem cell transplantation (HSCT). In industrialised economies like the U.S. and Europe, lack of physical exercise, obesity, and/or poor nutrition are to blame for one-third of all cancer diagnoses (globally), according to the Global Cancer Research Fund's 2018 report. Leukemia also develops with age and affects people of middle age at a rate of about 90%. A growing number of HSCT transplants in the region is likely to cause Asia Pacific to see the fastest increase during the projection period.
According to Coherent Market Insights, The market for Hematopoietic Stem Cell Transplantation is anticipated to reach US$ 2,092.6 million in 2020 and grow at a CAGR of 11.2% during the following five years (2020-2027).
Leading Companies in the Hematopoietic Stem Cell Transplantation Industry:
Pluristem Therapeutics Inc.
The business was established in 2001 and is located in Haifa, Israel. The business is working to commercially produce human placental adherent stromal cells for the treatment of diseases. Pluristem started using placenta cells called PLX to treat COVID-19 patients in 2020. The application from Pluristem to carry out a Phase II trial with their PLX cells received approval from the US Food and Drug Administration on May 8, 2020.
CellGenix GmbH,
The business was established in 1994 and the business is headquartered in Freiburg, Germany. A vast variety of cell kinds, bioprocessing containers, and other medical supplements are available from the company, which also produces cell treatment and medications. To develop next-generation automated cell and gene therapy manufacturing platforms, such as Ori Biotech in May 2020, CellGenix is forming relationships with businesses in those industries.
Regen Biopharma Inc.
The business was founded in 2012 and has its headquarters in La Mesa, California, United States. The company's main objective is to build platforms for translational medicine that will enable the commercialization of stem cell treatments. Regen BioPharma, Inc. reported in October 2022 that it has filed a provisional patent for a CAR-T cell that may draw in and educate naive T cells to kill cancer.